CDKL1: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: CDKL1

NCBI ID: G8814

CDKL1

CDKL1: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

Cyclin-dependent kinase-like 1 (CDKL1) is a protein that plays a crucial role in the regulation of cell cycle progression and the maintenance of cellular stability. CDKL1 functions as a negative regulator of the G1-phase, which helps ensure the timely completion of the cell cycle and the onset of cell division. Mutations in the CDKL1 gene have been implicated in various cancers, including breast, ovarian, and colorectal cancers. Therefore, targeting CDKL1 has emerged as a promising strategy for cancer treatment.

CDKL1 as a Drug Target

CDKL1 has been identified as a potential drug target due to its unique mechanism of action and its involvement in the regulation of cell growth and division. Activated CDKL1 has been shown to promote the growth and survival of cancer cells, while its inhibition has been shown to result in the inhibition of cancer cell growth and a decrease in the spread of cancer.

CDKL1 has been shown to play a role in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. For example, studies have shown that CDKL1 is highly expressed in breast cancer cells and is associated with poor prognosis. Additionally, CDKL1 has been shown to be overexpressed in ovarian cancer cells and is associated with poor outcomes.

Furthermore, CDKL1 has been shown to promote the development of cancer stem cells, which are capable of self-replicating and promoting the formation of new tumors. Therefore, targeting CDKL1 may be an effective way to prevent the development and progression of cancer stem cells.

CDKL1 as a Biomarker

CDKL1 has also been used as a biomarker for cancer diagnosis and monitoring. The expression of CDKL1 has been shown to be associated with the poor prognosis of various cancers. For example, studies have shown that high expression of CDKL1 is associated with poor prognosis in breast cancer.

Additionally, the levels of CDKL1 have been shown to be correlated with the tumor size and the number of cancer cells in a given tumor. This suggests that CDKL1 may be an effective biomarker for monitoring the effectiveness of cancer treatments.

CDKL1 Inhibition as a Cancer Treatment

CDKL1 inhibition has been shown to be an effective way to treat various cancers, including breast, ovarian, and colorectal cancers. Studies have shown that inhibition of CDKL1 using small molecules or antibodies has resulted in a reduction in cancer cell growth and a decrease in the spread of cancer.

For example, a small molecule called U012 has been shown to inhibit CDKL1 and result in the inhibition of cancer cell growth. Additionally, an antibody against CDKL1 has been shown to reduce the growth of cancer cells and the spread of cancer.

Conclusion

In conclusion, CDKL1 is a protein that plays a crucial role in the regulation of cell cycle progression and the maintenance of cellular stability. Its role in the development and progression of various cancers makes it an attractive target for cancer treatment. Further research is needed to fully understand the mechanism of action of CDKL1 and to develop safe and effective treatments. However, the potential of CDKL1 as a drug target and biomarker for cancer treatment is promising.

Protein Name: Cyclin Dependent Kinase Like 1

The "CDKL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDKL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets